Recent studies have shown an increasing incidence of colorectal
cancer in Asian populations. According to the Second Report of the National Cancer
Registry1, colorectal cancers accounted for 14.2% of male cancers and
10.1% of female cancers in Malaysia, making it the commonest cancer among men and
the third most common cancer among women respectively. Colorectal cancer is the
third commonest cause of cancer-related mortality in Malaysia.
1. Gerard Lim CC, Yahya H. Second Report of the National Cancer Registry, Cancer Incidence in Malaysia. National Cancer Registry, Ministry of Health, Kuala Lumpur, 2003.
At present, the National Cancer Registry only collects data on the prevalence and
incidence of colorectal cancer by age, sex and ethnicity.
The National Cancer Patient Registry-Colorectal Cancer (NCPR-CC) is established
as the first colorectal cancer registry in Malaysia to systematically collect data
on all aspects of colorectal cancer relevant to its prevention, management and treatment
evaluation in Malaysia. This information is useful in assisting the Ministry of
Health (MOH), Non-Governmental Organizations, private healthcare providers and industry
in program planning and evaluation, leading to improved colorectal cancer prevention,
management and control.
The objectives of the National Cancer Patient Registry- Colorectal Cancer are to:
- Determine the prevalence of colorectal cancer in Malaysia.
- Determine the sociodemographic profiles of these patients.
- Determine the risk factors in the patients with colorectal cancer.
- Determine the histological types and stages of presentation of colorectal cancer.
- Evaluate and monitor the outcomes of surgery and oncology therapy based on selected
performance indicators such as
- disease-free survival rates
- complications of treatment
- side-effects of treatment
- patient’s quality of life
- Determine the cost burden to the nation by colorectal cancer and the cost-effectiveness
of treatment and prevention programs.
Selection of subjects
Being a patient registry, the eligibility criterion is
deliberately broad (any patients undergoing treatment for colorectal cancer at
any clinical centres) to reflect real world practice and to ensure the sample is
representative of the population at large with colorectal cancer.
All histologically verified primary colorectal
cancer cases from participating sites (irrespective of the staging,
histopathology, duration of the disease) reported during the study period.
Any patient who received their treatment at
participating study sites not within the study period. Anal cancers and
metastatic lesions to the colorectum are excluded.